A Comparison of US, Europe, Japan and India Biosimilar Regulation
Abstract
Biosimilars have emerged as a crucial alternative to reference biologics, offering cost-effective treatment options while maintaining comparable efficacy and safety. Regulatory pathways for biosimilars differ across key global markets, including the United State (US), European Union (EU), India and Japan, reflecting distinct approaches to approval, evaluation, and market entry.
The EU a pioneer in biosimilar regulations, established a well- defined approval framework under the European Medicines Agency (EMA), setting global standards. The US Food and Drug Administration (FDA)follows the Biologics Price Competition and Innovation Act (BPCIA), which provides a structured but rigorous pathway for biosmilar approval. India, an emerging biosmilar hub, has developed guidelines that emphasize comparability studies, balancing affordability with regulatory stringency. Japan, under the Pharmaceutical and Medical Devices Agency (PMDA), follow a case-by-case approach, ensuring biosmilars meet high safety and efficacy standards.
This review article compares and contrasts biosimilar regulations across these regions, analyzing approval processes, interchangeability policies, clinical study requirements, and market dynamics. Understanding these regulatory landscapes is essential for global harmonization efforts, facilitating biosimilar access while ensuring patient safety.
Downloads
References
https://www.who.int/publications/m/item/sbp-trs-977-Annex-2
2. Research C for DE and. Biosimilars Basics for Patients. FDA [Internet]. US: USFDA;08 Jan 2024 [cited 2025 Jan 22]. Available from:
https://www.fda.gov/drugs/biosimilars/biosimilars-basics-patients
3. Biosimilar medicines: Overview | European Medicines Agency [Internet].EU: ema.europa; 2025 [cited 2025 Jan 24]. Available from:
https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview
4. Pineda C, Castañeda Hernández G, Jacobs IA, Alvarez DF, Carini C. Assessing the Immunogenicity of Biopharmaceuticals. Biodrugs [Internet]. Biodrug; 2016 Apr 20 [cited 2025 Jan 24];30:195–206. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875071/
5. Christl L. Food and Drug Administration. FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US [Internet]. US:USFDA [cited 2025 Jan 30]. Available from:
https://www.fda.gov/files/drugs/published/FDA%E2%80%99s-Overview-of-the-Regulatory-Guidance-for-the-Development-and-Approval-of-Biosimilar-Products-in-the-US.pdf
6. Research C for DE and. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product [Internet]. US: USFDA, CDER; 2020 Apr 24 [cited 2025 Jan 30]. Available from:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product
7. European Medicines Agency. Similar biological medicinal products - Scientific guideline European Medicines Agency [Internet]. EU: ema.europa; 2014 Oct 29 [cited 2025 Jan 30]. Available from:
https://www.ema.europa.eu/en/similar-biological-medicinal-products-scientific-guideline
8. Biosimilar medicines: Overview | European Medicines Agency [Internet]. EU: ema.europa; 2014 Oct 29 [cited 2025 Jan 30]. Available from:
https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview
9. Biosimilar Regulation and Guidelines in Japan. Pharmaceuticals and Medical Devices Agency PMDA HAYAMIZU Kenji [Internet]. Japan: PMDA; 2023 Aug 31 [cited 2025 Feb 01]. Available from:
https://www.pmda.go.jp/files/000267474.pdf
10. Japanese guidelines for biosimilars. Pharmaceuticals and Medical Devices Agency [Internet]. Gabionline; 2016 Oct 21 [cited 2025 Feb 01]. Available from:
https://www.gabionline.net/guidelines/Japanese-guidelines-for-biosimilars
11. Central Drugs Standard Control Organization. Guidelines on similar biologics: Regulatory Requirements for Marketing Authorization in India [Internet]. India: CDSCO; 2016 [cited 2025 Feb 01]. Available from:
https://ibkp.dbtindia.gov.in/DBT_Content_Test/CMS/Guidelines/20181115140059519_Guidelines-on-Similar-Biologics-2016.pdf
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
